Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies.
about
Intrabody and Parkinson's diseaseThe P42 peptide and Peptide-based therapies for Huntington's diseaseMechanisms of RNA-induced toxicity in CAG repeat disordersIntrabodies as neuroprotective therapeuticsPassive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body diseaseMonoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment.Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease.Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm.Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicityAn scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicityConformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity.Probing the metabolic aberrations underlying mutant huntingtin toxicity in yeast and assessing their degree of preservation in humans and mice.Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice.Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease.Neurodegenerative models in Drosophila: polyglutamine disorders, Parkinson disease, and amyotrophic lateral sclerosis.Systemic delivery of P42 peptide: a new weapon to fight Huntington's disease.Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments.Grape-seed polyphenolic extract improves the eye phenotype in a Drosophila model of tauopathy.Selective blockade of trypanosomatid protein synthesis by a recombinant antibody anti-Trypanosoma cruzi P2β proteinDifferential nuclear localization of complexes may underlie in vivo intrabody efficacy in Huntington's disease.Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease.POTENTIAL APPLICATION OF GRAPE DERIVED POLYPHENOLS IN HUNTINGTON'S DISEASEPalmitoyl-protein thioesterase 1 deficiency in Drosophila melanogaster causes accumulation of abnormal storage material and reduced life spanA huntingtin peptide inhibits polyQ-huntingtin associated defectsSelection and characterization of llama single domain antibodies against N-terminal huntingtinEffects on murine behavior and lifespan of selectively decreasing expression of mutant huntingtin allele by supt4h knockdownExpanded polyglutamine-binding peptoid as a novel therapeutic agent for treatment of Huntington's disease.Α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration.The Aggregation Inhibitor Peptide QBP1 as a Therapeutic Molecule for the Polyglutamine Neurodegenerative Diseases.Huntingtin aggregation kinetics and their pathological role in a Drosophila Huntington's disease modelIBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CA.The emerging role of the first 17 amino acids of huntingtin in Huntington's diseaseAnti-Aβ single-chain variable fragment antibodies exert synergistic neuroprotective activities in Drosophila models of Alzheimer's diseaseTranscriptional dysregulation of inflammatory/immune pathways after active vaccination against Huntington's diseaseSuppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtinProtein-based tumor molecular imaging probes.Immunological features of alpha-synuclein in Parkinson's disease.Evidence for prion-like mechanisms in several neurodegenerative diseases: potential implications for immunotherapyAntibody Engineering & Therapeutics 2016: The Antibody Society's annual meeting, December 11-15, 2016, San Diego, CAPhosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity.
P2860
Q24653530-C9E942C7-800A-4693-8525-DA24687D5598Q26764930-873357A3-57B5-45AD-A677-F5BFC056C7BFQ26860030-6C1C02F8-1279-4EBE-A8A4-4F138D8AE73DQ27003896-7C86ECB1-D4C4-4474-A96C-BF47C9373AF6Q28740551-BF993046-C4AB-4125-9693-BF39B17ED7D5Q30490726-BF6DE1C4-D8E3-42A2-A421-A5FC396BBF95Q30493159-E1D0337A-F063-4C37-A0E5-DA3D0CAFC5C5Q30980477-B70F64E5-0014-4520-BC31-B1F3CC5199DBQ33280345-A0884900-0BC4-4150-BE54-9D486F8F664AQ33317678-FD10432C-DBB9-433E-B3C9-38CF2B1EC567Q33459255-8A1008C1-E68C-445A-AFB2-671A5F157F45Q33571914-D6C418BC-80C9-4AF1-B93B-CF262053B972Q33594383-8C93ACF5-4213-4ED8-9F24-07606EE794D5Q34077018-EADB9C31-3B4E-4240-821F-C353DA71A153Q34079770-05D6B781-D8FC-42F8-AD1D-97CD47289310Q34109060-56607642-05D8-433B-BF95-D019F01D2679Q34117333-BBCB64AB-4473-4A82-953A-1C689B05CAF1Q34143466-48315E42-6651-4B60-A1B7-1513DBE3C0EEQ34263241-8B8C9898-5EA7-4AC6-88EC-08B11DF33A65Q34313192-D4AD260A-03AA-4157-A002-425FA3DEAE3DQ34373713-8ABF6C82-2C24-4A03-A5D6-DC2B50E8CFFAQ34576042-FDAEE6D8-68FE-4F09-93D1-564202FAC2D3Q34588532-B0FED465-BB81-4791-963C-253FA3BF45CAQ34828144-A84D085F-F892-4156-8608-5263B952092FQ35123206-887A1CD8-E211-40E0-8346-95157EFD09DDQ35168414-F0F96892-61A5-4E7A-9208-3713303ED23FQ35244160-4C93761E-74E0-43C5-B567-8787911204D9Q35542169-47639739-AD48-49B2-8B18-EE7DD9F0F991Q35708355-0AB7EBFE-5382-4D74-8F90-0247443886D9Q35748307-EB278268-A078-48C2-8CE3-86BD40E5258FQ35992493-93FD5291-8B0B-47E4-9D9D-5AC49B3FEE7DQ36110838-C94DA2BF-6C66-416F-9FA1-C68C3A6EB58BQ36142379-748A9EBE-B0E0-44F7-9EBC-C3D5F3672732Q36142398-1370FE09-BC05-45F8-BE63-4AB0349C1A60Q36677547-D367D643-27A5-4ED7-BE59-542D5F847ADCQ36742911-C18C6F36-FE6A-459A-8197-19687E031CBAQ37232067-6826A037-CD58-4F16-89D7-FB38546C413BQ37280507-62588501-5083-4BC8-8645-CA5B101967B2Q37397677-FB4285B6-E9F2-4AEB-A11A-2E9DCD8A4EC2Q37447680-EE44FFE5-38B1-40AD-AAC4-409A858077B4
P2860
Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Suppression of Huntington's di ...... an single-chain Fv antibodies.
@ast
Suppression of Huntington's di ...... an single-chain Fv antibodies.
@en
type
label
Suppression of Huntington's di ...... an single-chain Fv antibodies.
@ast
Suppression of Huntington's di ...... an single-chain Fv antibodies.
@en
prefLabel
Suppression of Huntington's di ...... an single-chain Fv antibodies.
@ast
Suppression of Huntington's di ...... an single-chain Fv antibodies.
@en
P2093
P2860
P921
P356
P1476
Suppression of Huntington's di ...... man single-chain Fv antibodies
@en
P2093
Anne Messer
J Lawrence Marsh
Jack M Webster
James S Huston
Leslie M Thompson
Todd W Miller
P2860
P304
11563-11568
P356
10.1073/PNAS.0505321102
P407
P577
2005-08-01T00:00:00Z